Answers are grounded in this paper and cite their sources.
Platinum(IV), a pro-drug of platinum(II), was conjugated to poly(l-lysine) (PLL), and then assembled with poly(glutamic acid) (PGA) through a layer-by-layer (LbL) approach on colloidal silica templates. After removal of the templates, biodegradable PGA/PLL-Pt(IV) multilayer capsules (diameter = 0.5 μm) with 10 μg of platinum incorporated into each bilayer were obtained. Under acidic and/or reductive conditions, the amount and rate of platinum released from the capsules were increased, which are desirable traits for platinum-based anticancer drug delivery systems. Furthermore, in vitro evaluation showed that the PGA/PLL-Pt(IV) multilayer microcapsules displayed higher cytotoxicity (IC(50Pt) = 3.5 μg/mL) against colon cancer cells CT-26 than that of free cisplatin (IC(50Pt) = 8.6 μg/mL). This enhanced cytotoxicity was attributed to the effective internalization of the capsules by the cancer cells, which was observed by confocal laser scanning microscopy (CLSM) imaging.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: